← Back to Search

Alpha-2 Agonist

Guanfacine for Delirium

Phase 3

Waitlist Available

Led By Andrew Barker, MD

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from the time of icu admission up to 14 days

Awards & highlights

Study Summary

This trial investigates whether guanfacine reduces delirium in ICU patients compared to placebo, and whether it reduces the duration of delirium when given along with standard of care.

Eligible Conditions

Delirium

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from the time of icu admission up to 14 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from the time of icu admission up to 14 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and from the time of icu admission up to 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Delirium

Secondary outcome measures

Severity of Deliirum

Type of Delirium

Side effects data

From 2011 Phase 4 trial • 212 Patients • NCT00429273

36%

Decreased Appetite

34%

Insomnia

33%

Headache

26%

Irritability

23%

Abdominal Pain

23%

Sedation

23%

Lethargy

21%

Somnolence

17%

Fatigue

14%

Abdominal Pain Upper

11%

Affect Lability

10%

Dizziness

100%

80%

60%

40%

20%

Study treatment Arm

Group 1: Guan-Guan+Placebo

Group 2: Placebo-Placebo+DMPH

Group 3: Guan-Guan+DMPH

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: GuanfacineExperimental Treatment1 Intervention

Guanfacine immediate-release, 2mg dose, over-encapsulated tablet, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.

Group II: PlaceboPlacebo Group1 Intervention

Placebo, lactulose monohydrate, encapsulated, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Guanfacine

2008

Completed Phase 4

~2180

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor

1,581 Previous Clinical Trials

2,277,928 Total Patients Enrolled

2 Trials studying Delirium

67 Patients Enrolled for Delirium

Andrew Barker, MDPrincipal Investigator - University of Alabama at Birmingham

University of Alabama at Birmingham

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the federal government sanctioned Guanfacine for therapeutic use?

"There is both efficacy and safety data available for Guanfacine, so it was given a score of 3."

Answered by AI

What has been the general response to Guanfacine in previous research?

"As of now, there are 12 clinical trials still ongoing for Guanfacine. Out of these investigations, 2 have reached Phase 3. There are 83 different locations running these trials, with several in Palo Alto, California."

Answered by AI

What conditions does Guanfacine typically treat?

"Guanfacine is a medication that has diverse applications. For example, it can be used to treat migraines, attention deficit hyperactivity disorder (ADHD), and hypertension. Additionally, guanfacine can help prevent migraine headaches from occurring."

Answered by AI

Are we still looking for participants in this experiment?

"This clinical trial, as reported on clinicaltrials.gov, is not currently searching for candidates. The study was first posted on 11/23/2020 and was most recently updated on 11/14/2022. Although this study is not recruiting patients at this time, there are 337 other clinical trials that are accepting patients right now."

Answered by AI

How many total individuals are participating in this clinical trial?

"As of now, this clinical trial is no longer looking for new patients as it has already reached its recruitment goal. The study was posted on 11/23/2020 and was most recently updated on 11/14/2022. However, there are 325 other trials searching for delirium patients and 12 studies involving Guanfacine that are still recruiting participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The Effect of Guanfacine on Delirium in Critically Ill Patients

Andrew Barker 2020. "The Effect of Guanfacine on Delirium in Critically Ill Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04578886.